Quanterix partner receives China approval for neurology tests

Quanterix (QTRX) announced that China's NMPA approved its HD-X and SR-X instruments and four neurology biomarker kits via partner Innovita, expanding its IVD access in China. The approvals include kits for p-Tau 217, GFAP, p-Tau 181, and NfL. The company aims to convert research tech into clinical IVD revenue through regional partners.

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.

Quanterix (NASDAQ:QTRX) reported Q2 cash use of $5.7M and cash of $96.9M. Simoa revenue was $20.6M, Spatial $12.3M, and GAAP gross margin 38.5%. Management guided Q3 revenue flat to slightly above Q2 and cited Akoya integration, $85M annualized savings, and commercial reorganization. FDA timing for LucentAD Complete is targeted for late 2026.

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2026 Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends

Quanterix Corp. (QTRX) appointed Jason Faessler as CFO effective June 22, succeeding Vandana Sriram, who has served since August 2023 and will step down. Faessler joins from Bruker Corp., where he led global FP&A and Americas finance. Shares fell in premarket, down 3.09% to $3.0332 after a 5.15% decline Monday.